<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31756952</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>04</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>23</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">5822</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20235822</ELocationID>
        <Abstract>
          <AbstractText>Transforming growth factor-beta (TGF-β) signaling is one of the important cellular pathways that play key roles for tissue maintenance. In particular, it is important in the context of inflammation and tumorigenesis by modulating cell growth, differentiation, apoptosis, and homeostasis. TGF-β receptor type 2 (<i>TGFBR2</i>) mutations affected by a mismatch repair deficiency causes colorectal cancers (CRCs) with microsatellite instability, which is, however, associated with relatively better survival rates. On the other hand, loss of <i>SMAD4</i>, a transcription factor in the TGF-β superfamily signaling, promotes tumor progression. Loss of heterozygosity on chromosome 18 can case SMAD4-deficient CRC, which results in poorer patients' survival. Such bidirectional phenomenon driven by TGF-β signaling insufficiency reflects the complexity of this signaling pathway in CRC. Moreover, recent understanding of CRC at the molecular level (consensus molecular subtype classification) provides deep insight into the important roles of TGF-β signaling in the tumor microenvironment. Here we focus on the TGF-β signaling in CRC and its interaction with the tumor microenvironment. We summarize the molecular mechanisms of CRC tumorigenesis and progression caused by disruption of TGF-β signaling by cancer epithelial cells and host stromal cells.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Itatani</LastName>
            <ForeName>Yoshiro</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-7356-7065</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawada</LastName>
            <ForeName>Kenji</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-4336-6937</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakai</LastName>
            <ForeName>Yoshiharu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">SMAD4</Keyword>
        <Keyword MajorTopicYN="N">TGF-β signaling</Keyword>
        <Keyword MajorTopicYN="N">colorectal cancer</Keyword>
        <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31756952</ArticleId>
        <ArticleId IdType="pmc">PMC6929101</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms20235822</ArticleId>
        <ArticleId IdType="pii">ijms20235822</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Jung B., Staudacher J.J., Beauchamp D. Transforming Growth Factor beta Superfamily Signaling in Development of Colorectal Cancer. Gastroenterology. 2017;152:36–52. doi: 10.1053/j.gastro.2016.10.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2016.10.015</ArticleId>
            <ArticleId IdType="pmc">PMC5550896</ArticleId>
            <ArticleId IdType="pubmed">27773809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 2012;13:616–630. doi: 10.1038/nrm3434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3434</ArticleId>
            <ArticleId IdType="pmc">PMC4027049</ArticleId>
            <ArticleId IdType="pubmed">22992590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Principe D.R., Doll J.A., Bauer J., Jung B., Munshi H.G., Bartholin L., Pasche B., Lee C., Grippo P.J. TGF-β: Duality of Function Between Tumor Prevention and Carcinogenesis. J. Natl. Cancer Inst. 2014;106 doi: 10.1093/jnci/djt369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djt369</ArticleId>
            <ArticleId IdType="pmc">PMC3952197</ArticleId>
            <ArticleId IdType="pubmed">24511106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005;19:2783–2810. doi: 10.1101/gad.1350705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1350705</ArticleId>
            <ArticleId IdType="pubmed">16322555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ihara S., Hirata Y., Koike K. TGF-β in inflammatory bowel disease: A key regulator of immune cells, epithelium, and the intestinal microbiota. J. Gastroenterol. 2017;52:777–787. doi: 10.1007/s00535-017-1350-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-017-1350-1</ArticleId>
            <ArticleId IdType="pubmed">28534191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batlle R., Andrés E., Gonzalez L., Llonch E., Igea A., Gutierrez-Prat N., Berenguer-Llergo A., Nebreda A.R. Regulation of tumor angiogenesis and mesenchymal–endothelial transition by p38α through TGF-β and JNK signaling. Nat. Commun. 2019;10:3071. doi: 10.1038/s41467-019-10946-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-10946-y</ArticleId>
            <ArticleId IdType="pmc">PMC6624205</ArticleId>
            <ArticleId IdType="pubmed">31296856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muñoz N.M., Upton M., Rojas A., Washington M.K., Lin L., Chytil A., Sozmen E.G., Madison B.B., Pozzi A., Moon R.T., et al.  Transforming Growth Factor β Receptor Type II Inactivation Induces the Malignant Transformation of Intestinal Neoplasms Initiated by Apc Mutation. Cancer Res. 2006;66:9837. doi: 10.1158/0008-5472.CAN-06-0890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-0890</ArticleId>
            <ArticleId IdType="pubmed">17047044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itatani Y., Kawada K., Fujishita T., Kakizaki F., Hirai H., Matsumoto T., Iwamoto M., Inamoto S., Hatano E., Hasegawa S., et al.  Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis. Gastroenterology. 2013;145:1064–1075. doi: 10.1053/j.gastro.2013.07.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2013.07.033</ArticleId>
            <ArticleId IdType="pubmed">23891973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inamoto S., Itatani Y., Yamamoto T., Minamiguchi S., Hirai H., Iwamoto M., Hasegawa S., Taketo M.M., Sakai Y., Kawada K. Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis. Clin. Cancer Res. 2016;22:492–501. doi: 10.1158/1078-0432.CCR-15-0726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0726</ArticleId>
            <ArticleId IdType="pubmed">26341919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto T., Kawada K., Itatani Y., Inamoto S., Okamura R., Iwamoto M., Miyamoto E., Chen-Yoshikawa T.F., Hirai H., Hasegawa S., et al.  Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis. Clin. Cancer Res. 2017;23:833–844. doi: 10.1158/1078-0432.CCR-16-0520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0520</ArticleId>
            <ArticleId IdType="pubmed">27492974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa R., Yamamoto T., Hirai H., Hanada K., Kiyasu Y., Nishikawa G., Mizuno R., Inamoto S., Itatani Y., Sakai Y., et al.  Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis. Clin. Cancer Res. 2019;25:2887–2899. doi: 10.1158/1078-0432.CCR-18-3684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-3684</ArticleId>
            <ArticleId IdType="pubmed">30705034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guinney J., Dienstmann R., Wang X., de Reynies A., Schlicker A., Soneson C., Marisa L., Roepman P., Nyamundanda G., Angelino P., et al.  The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015;21:1350–1356. doi: 10.1038/nm.3967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3967</ArticleId>
            <ArticleId IdType="pmc">PMC4636487</ArticleId>
            <ArticleId IdType="pubmed">26457759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Miranda N.F.C.C., van Dinther M., van den Akker B.E.W.M., van Wezel T., ten Dijke P., Morreau H. Transforming Growth Factor β Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2. Gastroenterology. 2015;148:1427–1437. doi: 10.1053/j.gastro.2015.02.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2015.02.052</ArticleId>
            <ArticleId IdType="pubmed">25736321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grady W.M. Polymerase Slippage Restoration of Frameshifted TGFBR2 in Colorectal Cancer: A Novel Paradigm. Gastroenterology. 2015;148:1276–1279. doi: 10.1053/j.gastro.2015.04.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2015.04.023</ArticleId>
            <ArticleId IdType="pubmed">25921376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth A.D., Delorenzi M., Tejpar S., Yan P., Klingbiel D., Fiocca R., d’Ario G., Cisar L., Labianca R., Cunningham D., et al.  Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J. Natl. Cancer Inst. 2012;104:1635–1646. doi: 10.1093/jnci/djs427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djs427</ArticleId>
            <ArticleId IdType="pubmed">23104212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss A., Attisano L. The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev. Dev. Biol. 2013;2:47–63. doi: 10.1002/wdev.86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wdev.86</ArticleId>
            <ArticleId IdType="pubmed">23799630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Malpartida P., Batet M., Kaczmarska Z., Freier R., Gomes T., Aragón E., Zou Y., Wang Q., Xi Q., Ruiz L., et al.  Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors. Nat. Commun. 2017;8:2070. doi: 10.1038/s41467-017-02054-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-02054-6</ArticleId>
            <ArticleId IdType="pmc">PMC5727232</ArticleId>
            <ArticleId IdType="pubmed">29234012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao Y., Baker D., Ten Dijke P. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int. J. Mol. Sci. 2019;20:2767.  doi: 10.3390/ijms20112767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20112767</ArticleId>
            <ArticleId IdType="pmc">PMC6600375</ArticleId>
            <ArticleId IdType="pubmed">31195692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700. doi: 10.1016/S0092-8674(03)00432-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(03)00432-X</ArticleId>
            <ArticleId IdType="pubmed">12809600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang C. Agonists and Antagonists of TGF-beta Family Ligands. Cold Spring Harb. Perspect. Biol. 2016;8 doi: 10.1101/cshperspect.a021923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a021923</ArticleId>
            <ArticleId IdType="pmc">PMC4968162</ArticleId>
            <ArticleId IdType="pubmed">27413100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature. 2003;425:577–584. doi: 10.1038/nature02006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature02006</ArticleId>
            <ArticleId IdType="pubmed">14534577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simoneaux R. The Four Colorectal Cancer Consensus Molecular Subtypes. Oncol. Times. 2018;40:10–11. doi: 10.1097/01.COT.0000531932.39051.dd.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.COT.0000531932.39051.dd</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shima K., Morikawa T., Yamauchi M., Kuchiba A., Imamura Y., Liao X., Meyerhardt J.A., Fuchs C.S., Ogino S. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS ONE. 2011;6:e25062.  doi: 10.1371/journal.pone.0025062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0025062</ArticleId>
            <ArticleId IdType="pmc">PMC3176811</ArticleId>
            <ArticleId IdType="pubmed">21949851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., French A.J., Kabat B., Foster N.R., Torri V., et al.  Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010;28:3219–3226. doi: 10.1200/JCO.2009.27.1825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.27.1825</ArticleId>
            <ArticleId IdType="pmc">PMC2903323</ArticleId>
            <ArticleId IdType="pubmed">20498393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dienstmann R., Vermeulen L., Guinney J., Kopetz S., Tejpar S., Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer. 2017;17:79–92. doi: 10.1038/nrc.2016.126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc.2016.126</ArticleId>
            <ArticleId IdType="pubmed">28050011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Jr., Kinzler K.W. Cancer genome landscapes. Science. 2013;339:1546–1558. doi: 10.1126/science.1235122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1235122</ArticleId>
            <ArticleId IdType="pmc">PMC3749880</ArticleId>
            <ArticleId IdType="pubmed">23539594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voorneveld P.W., Jacobs R.J., Kodach L.L., Hardwick J.C. A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer. Transl. Oncol. 2015;8:18–24. doi: 10.1016/j.tranon.2014.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tranon.2014.11.003</ArticleId>
            <ArticleId IdType="pmc">PMC4350636</ArticleId>
            <ArticleId IdType="pubmed">25749173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan P., Klingbiel D., Saridaki Z., Ceppa P., Curto M., McKee T.A., Roth A., Tejpar S., Delorenzi M., Bosman F.T., et al.  Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer. Clin. Cancer Res. 2016;22:3037–3047. doi: 10.1158/1078-0432.CCR-15-0939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0939</ArticleId>
            <ArticleId IdType="pubmed">26861460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuno T., Cloyd J.M., Vicente D., Omichi K., Chun Y.S., Kopetz S.E., Maru D., Conrad C., Tzeng C.D., Wei S.H., et al.  SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. Eur. J. Surg. Oncol. 2018;44:684–692. doi: 10.1016/j.ejso.2018.02.247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejso.2018.02.247</ArticleId>
            <ArticleId IdType="pubmed">29551247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okita A., Takahashi S., Ouchi K., Inoue M., Watanabe M., Endo M., Honda H., Yamada Y., Ishioka C. Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget. 2018;9:18698–18711. doi: 10.18632/oncotarget.24617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.24617</ArticleId>
            <ArticleId IdType="pmc">PMC5922348</ArticleId>
            <ArticleId IdType="pubmed">29721154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mooi J.K., Wirapati P., Asher R., Lee C.K., Savas P., Price T.J., Townsend A., Hardingham J., Buchanan D., Williams D., et al.  The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: Molecular analysis of the AGITG MAX clinical trial. Ann. Oncol. 2018;29:2240–2246. doi: 10.1093/annonc/mdy410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy410</ArticleId>
            <ArticleId IdType="pubmed">30247524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sveen A., Bruun J., Eide P.W., Eilertsen I.A., Ramirez L., Murumägi A., Arjama M., Danielsen S.A., Kryeziu K., Elez E., et al.  Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clin. Cancer Res. 2018;24:794. doi: 10.1158/1078-0432.CCR-17-1234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-1234</ArticleId>
            <ArticleId IdType="pubmed">29242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pino M.S., Kikuchi H., Zeng M., Herraiz M.T., Sperduti I., Berger D., Park D.Y., Iafrate A.J., Zukerberg L.R., Chung D.C. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology. 2010;138:1406–1417. doi: 10.1053/j.gastro.2009.12.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2009.12.010</ArticleId>
            <ArticleId IdType="pmc">PMC2846966</ArticleId>
            <ArticleId IdType="pubmed">20026115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fessler E., Drost J., van Hooff S.R., Linnekamp J.F., Wang X., Jansen M., De Sousa E Melo F., Prasetyanti P.R., Ijspeert J.E., Franitza M., et al.  TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol. Med. 2016;8:745–760. doi: 10.15252/emmm.201606184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201606184</ArticleId>
            <ArticleId IdType="pmc">PMC4931289</ArticleId>
            <ArticleId IdType="pubmed">27221051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336. doi: 10.1126/science.7761852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.7761852</ArticleId>
            <ArticleId IdType="pubmed">7761852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubenstein J.H., Enns R., Heidelbaugh J., Barkun A. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology. 2015;149:777–782. doi: 10.1053/j.gastro.2015.07.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2015.07.036</ArticleId>
            <ArticleId IdType="pubmed">26226577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasen H.F., Blanco I., Aktan-Collan K., Gopie J.P., Alonso A., Aretz S., Bernstein I., Bertario L., Burn J., Capella G., et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): Recommendations by a group of European experts. Gut. 2013;62:812–823. doi: 10.1136/gutjnl-2012-304356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2012-304356</ArticleId>
            <ArticleId IdType="pmc">PMC3647358</ArticleId>
            <ArticleId IdType="pubmed">23408351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamura K., Kaneda M., Futagawa M., Takeshita M., Kim S., Nakama M., Kawashita N., Tatsumi-Miyajima J. Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome. Int. J. Clin. Oncol. 2019;24:999–1011. doi: 10.1007/s10147-019-01494-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10147-019-01494-y</ArticleId>
            <ArticleId IdType="pubmed">31273487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haraldsdottir S., Hampel H., Wu C., Weng D.Y., Shields P.G., Frankel W.L., Pan X., de la Chapelle A., Goldberg R.M., Bekaii-Saab T. Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genet. Med. 2016;18:863–868. doi: 10.1038/gim.2015.184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gim.2015.184</ArticleId>
            <ArticleId IdType="pmc">PMC5489337</ArticleId>
            <ArticleId IdType="pubmed">26866578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y., Pasche B. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum. Mol. Genet. 2007;16 Spec No 1:R14–R20. doi: 10.1093/hmg/ddl486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddl486</ArticleId>
            <ArticleId IdType="pmc">PMC2637552</ArticleId>
            <ArticleId IdType="pubmed">17613544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakai E., Nakayama M., Oshima H., Kouyama Y., Niida A., Fujii S., Ochiai A., Nakayama K.I., Mimori K., Suzuki Y., et al.  Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer. Cancer Res. 2018;78:1334–1346. doi: 10.1158/0008-5472.CAN-17-3303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-3303</ArticleId>
            <ArticleId IdType="pubmed">29282223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeda H., Kataoka S., Nakayama M., Ali M.A.E., Oshima H., Yamamoto D., Park J.-W., Takegami Y., An T., Jenkins N.A., et al.  CRISPR-Cas9–mediated gene knockout in intestinal tumor organoids provides functional validation for colorectal cancer driver genes. Proc. Natl. Acad. Sci. USA. 2019;116:15635. doi: 10.1073/pnas.1904714116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1904714116</ArticleId>
            <ArticleId IdType="pmc">PMC6681705</ArticleId>
            <ArticleId IdType="pubmed">31300537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinheiro M., Pinto C., Peixoto A., Veiga I., Lopes P., Henrique R., Baldaia H., Carneiro F., Seruca R., Tomlinson I., et al.  Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. Br. J. Cancer. 2015;113:686–692. doi: 10.1038/bjc.2015.281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2015.281</ArticleId>
            <ArticleId IdType="pmc">PMC4647680</ArticleId>
            <ArticleId IdType="pubmed">26247575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogino S., Giannakis M. Immunoscore for (colorectal) cancer precision medicine. Lancet. 2018;391:2084–2086. doi: 10.1016/S0140-6736(18)30953-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)30953-X</ArticleId>
            <ArticleId IdType="pmc">PMC5984170</ArticleId>
            <ArticleId IdType="pubmed">29754776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Principe D.R., DeCant B., Staudacher J., Vitello D., Mangan R.J., Wayne E.A., Mascariñas E., Diaz A.M., Bauer J., McKinney R.D., et al.  Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation. Oncotarget. 2017;8:3826. doi: 10.18632/oncotarget.9830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.9830</ArticleId>
            <ArticleId IdType="pmc">PMC5354798</ArticleId>
            <ArticleId IdType="pubmed">27270652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oshima H., Nakayama M., Han T.S., Naoi K., Ju X., Maeda Y., Robine S., Tsuchiya K., Sato T., Sato H., et al.  Suppressing TGFbeta signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer. Cancer Res. 2015;75:766–776. doi: 10.1158/0008-5472.CAN-14-2036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-2036</ArticleId>
            <ArticleId IdType="pubmed">25687406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris S.M., Davison J., Carter K.T., O’Leary R.M., Trobridge P., Knoblaugh S.E., Myeroff L.L., Markowitz S.D., Brett B.T., Scheetz T.E., et al.  Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms. Int. J. Cancer. 2017;140:853–863. doi: 10.1002/ijc.30491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.30491</ArticleId>
            <ArticleId IdType="pmc">PMC5316486</ArticleId>
            <ArticleId IdType="pubmed">27790711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miguchi M., Hinoi T., Shimomura M., Adachi T., Saito Y., Niitsu H., Kochi M., Sada H., Sotomaru Y., Ikenoue T., et al.  Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation. PLoS ONE. 2016;11:e0166422.  doi: 10.1371/journal.pone.0166422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0166422</ArticleId>
            <ArticleId IdType="pmc">PMC5105946</ArticleId>
            <ArticleId IdType="pubmed">27835699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferreira I.G., Pucci M., Venturi G., Malagolini N., Chiricolo M., Dall’Olio F. Glycosylation as a Main Regulator of Growth and Death Factor Receptors Signaling. Int. J. Mol. Sci. 2018;19:580.  doi: 10.3390/ijms19020580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19020580</ArticleId>
            <ArticleId IdType="pmc">PMC5855802</ArticleId>
            <ArticleId IdType="pubmed">29462882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J., Katzenmaier E.M., Kopitz J., Gebert J. Reconstitution of TGFBR2 in HCT116 colorectal cancer cells causes increased LFNG expression and enhanced N-acetyl-d-glucosamine incorporation into Notch1. Cell. Signal. 2016;28:1105–1113. doi: 10.1016/j.cellsig.2016.04.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2016.04.012</ArticleId>
            <ArticleId IdType="pubmed">27156840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J., Fricke F., Warnken U., Schnölzer M., Kopitz J., Gebert J. Reconstitution of TGFBR2-Mediated Signaling Causes Upregulation of GDF-15 in HCT116 Colorectal Cancer Cells. PLoS ONE. 2015;10:e0131506.  doi: 10.1371/journal.pone.0131506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0131506</ArticleId>
            <ArticleId IdType="pmc">PMC4484253</ArticleId>
            <ArticleId IdType="pubmed">26114631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fricke F., Michalak M., Warnken U., Hausser I., Schnolzer M., Kopitz J., Gebert J. SILAC-Based Quantification of TGFBR2-Regulated Protein Expression in Extracellular Vesicles of Microsatellite Unstable Colorectal Cancers. Int. J. Mol. Sci. 2019;20:4162.  doi: 10.3390/ijms20174162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20174162</ArticleId>
            <ArticleId IdType="pmc">PMC6747473</ArticleId>
            <ArticleId IdType="pubmed">31454892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fricke F., Mussack V., Buschmann D., Hausser I., Pfaffl M.W., Kopitz J., Gebert J. TGFBR2-dependent alterations of microRNA profiles in extracellular vesicles and parental colorectal cancer cells. Int. J. Oncol. 2019;55:925–937. doi: 10.3892/ijo.2019.4859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2019.4859</ArticleId>
            <ArticleId IdType="pubmed">31432155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weinberg R.A. Tumor suppressor genes. Biol. Cancer. 2013;2:231–274.</Citation>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas Network  Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337. doi: 10.1038/nature11252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature11252</ArticleId>
            <ArticleId IdType="pmc">PMC3401966</ArticleId>
            <ArticleId IdType="pubmed">22810696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matano M., Date S., Shimokawa M., Takano A., Fujii M., Ohta Y., Watanabe T., Kanai T., Sato T. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat. Med. 2015;21:256–262. doi: 10.1038/nm.3802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3802</ArticleId>
            <ArticleId IdType="pubmed">25706875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang D., Sun W., Zhou Y., Li P., Chen F., Chen H., Xia D., Xu E., Lai M., Wu Y., et al.  Mutations of key driver genes in colorectal cancer progression and metastasis. Cancer Metastasis Rev. 2018;37:173–187. doi: 10.1007/s10555-017-9726-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-017-9726-5</ArticleId>
            <ArticleId IdType="pubmed">29322354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takaku K., Oshima M., Miyoshi H., Matsui M., Seldin M.F., Taketo M.M. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 1998;92:645–656. doi: 10.1016/S0092-8674(00)81132-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)81132-0</ArticleId>
            <ArticleId IdType="pubmed">9506519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitamura T., Kometani K., Hashida H., Matsunaga A., Miyoshi H., Hosogi H., Aoki M., Oshima M., Hattori M., Takabayashi A., et al.  SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat. Genet. 2007;39:467–475. doi: 10.1038/ng1997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1997</ArticleId>
            <ArticleId IdType="pubmed">17369830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riggins G.J., Kinzler K.W., Vogelstein B., Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Res. 1997;57:2578–2580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9205057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salovaara R., Roth S., Loukola A., Launonen V., Sistonen P., Avizienyte E., Kristo P., Jarvinen H., Souchelnytskyi S., Sarlomo-Rikala M., et al.  Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut. 2002;51:56–59. doi: 10.1136/gut.51.1.56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gut.51.1.56</ArticleId>
            <ArticleId IdType="pmc">PMC1773263</ArticleId>
            <ArticleId IdType="pubmed">12077092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng D., Zhao S., Tang H., Zhang D., Sun H., Yu F., Jiang W., Yue B., Wang J., Zhang M., et al.  MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. Oncotarget. 2016;7:45199–45213. doi: 10.18632/oncotarget.9900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.9900</ArticleId>
            <ArticleId IdType="pmc">PMC5216716</ArticleId>
            <ArticleId IdType="pubmed">27286257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu P., Lin X., Feng X.H. Posttranslational Regulation of Smads. Cold Spring Harb. Perspect. Biol. 2016;8 doi: 10.1101/cshperspect.a022087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a022087</ArticleId>
            <ArticleId IdType="pmc">PMC5131773</ArticleId>
            <ArticleId IdType="pubmed">27908935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fei T., Xia K., Li Z., Zhou B., Zhu S., Chen H., Zhang J., Chen Z., Xiao H., Han J.-D.J., et al.  Genome-wide mapping of SMAD target genes reveals the role of BMP signaling in embryonic stem cell fate determination. Genome Res. 2010;20:36–44. doi: 10.1101/gr.092114.109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gr.092114.109</ArticleId>
            <ArticleId IdType="pmc">PMC2798829</ArticleId>
            <ArticleId IdType="pubmed">19926752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kennedy B.A., Deatherage D.E., Gu F., Tang B., Chan M.W., Nephew K.P., Huang T.H., Jin V.X. ChIP-seq defined genome-wide map of TGFbeta/SMAD4 targets: Implications with clinical outcome of ovarian cancer. PLoS ONE. 2011;6:e22606.  doi: 10.1371/journal.pone.0022606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0022606</ArticleId>
            <ArticleId IdType="pmc">PMC3143154</ArticleId>
            <ArticleId IdType="pubmed">21799915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Means A.L., Freeman T.J., Zhu J., Woodbury L.G., Marincola-Smith P., Wu C., Meyer A.R., Weaver C.J., Padmanabhan C., An H., et al.  Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cell. Mol. Gastroenterol. Hepatol. 2018;6:257–276. doi: 10.1016/j.jcmgh.2018.05.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmgh.2018.05.006</ArticleId>
            <ArticleId IdType="pmc">PMC6083016</ArticleId>
            <ArticleId IdType="pubmed">30109253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kitamura T., Fujishita T., Loetscher P., Revesz L., Hashida H., Kizaka-Kondoh S., Aoki M., Taketo M.M. Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc. Natl. Acad. Sci. USA. 2010;107:13063–13068. doi: 10.1073/pnas.1002372107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1002372107</ArticleId>
            <ArticleId IdType="pmc">PMC2919974</ArticleId>
            <ArticleId IdType="pubmed">20616008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirai H., Fujishita T., Kurimoto K., Miyachi H., Kitano S., Inamoto S., Itatani Y., Saitou M., Maekawa T., Taketo M.M. CCR1-mediated accumulation of myeloid cells in the liver microenvironment promoting mouse colon cancer metastasis. Clin. Exp. Metastasis. 2014;31:977–989. doi: 10.1007/s10585-014-9684-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10585-014-9684-z</ArticleId>
            <ArticleId IdType="pmc">PMC4256518</ArticleId>
            <ArticleId IdType="pubmed">25326065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao M., Mishra L., Deng C.-X. The role of TGF-β/SMAD4 signaling in cancer. Int. J. Biol. Sci. 2018;14:111–123. doi: 10.7150/ijbs.23230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/ijbs.23230</ArticleId>
            <ArticleId IdType="pmc">PMC5821033</ArticleId>
            <ArticleId IdType="pubmed">29483830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roelands J., Kuppen P.J.K., Vermeulen L., Maccalli C., Decock J., Wang E., Marincola F.M., Bedognetti D., Hendrickx W. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. Int. J. Mol. Sci. 2017;18:2229.  doi: 10.3390/ijms18102229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms18102229</ArticleId>
            <ArticleId IdType="pmc">PMC5666908</ArticleId>
            <ArticleId IdType="pubmed">29064420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zonneville J., Safina A., Truskinovsky A.M., Arteaga C.L., Bakin A.V. TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. BMC Cancer. 2018;18:670. doi: 10.1186/s12885-018-4587-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-018-4587-z</ArticleId>
            <ArticleId IdType="pmc">PMC6008941</ArticleId>
            <ArticleId IdType="pubmed">29921235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itatani Y., Kawada K., Yamamoto T., Sakai Y. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int. J. Mol. Sci. 2018;19:1232.  doi: 10.3390/ijms19041232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19041232</ArticleId>
            <ArticleId IdType="pmc">PMC5979390</ArticleId>
            <ArticleId IdType="pubmed">29670046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Sheng J., Dai D., Liu T., Qi F. Smad4 acts as tumor suppressor by antagonizing lymphangiogenesis in colorectal cancer. Pathol. Res. Pract. 2015;211:286–292. doi: 10.1016/j.prp.2014.09.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.prp.2014.09.008</ArticleId>
            <ArticleId IdType="pubmed">25680269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X., Li X., Lv X., Xiao J., Liu B., Zhang Y. Smad4 Inhibits VEGF-A and VEGF-C Expressions via Enhancing Smad3 Phosphorylation in Colon Cancer. Anat. Rec. 2017;300:1560–1569. doi: 10.1002/ar.23610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ar.23610</ArticleId>
            <ArticleId IdType="pubmed">28445620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perekatt A.O., Shah P.P., Cheung S., Jariwala N., Wu A., Gandhi V., Kumar N., Feng Q., Patel N., Chen L., et al.  SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res. 2018;78:4878–4890. doi: 10.1158/0008-5472.CAN-18-0043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0043</ArticleId>
            <ArticleId IdType="pmc">PMC6125228</ArticleId>
            <ArticleId IdType="pubmed">29986996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freeman T.J., Smith J.J., Chen X., Washington M.K., Roland J.T., Means A.L., Eschrich S.A., Yeatman T.J., Deane N.G., Beauchamp R.D. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Gastroenterology. 2012;142:562–571. doi: 10.1053/j.gastro.2011.11.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2011.11.026</ArticleId>
            <ArticleId IdType="pmc">PMC3343368</ArticleId>
            <ArticleId IdType="pubmed">22115830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B., Zhang B., Chen X., Bae S., Singh K., Washington M.K., Datta P.K. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br. J. Cancer. 2014;110:946–957. doi: 10.1038/bjc.2013.789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.789</ArticleId>
            <ArticleId IdType="pmc">PMC3929873</ArticleId>
            <ArticleId IdType="pubmed">24384683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papageorgis P., Cheng K., Ozturk S., Gong Y., Lambert A.W., Abdolmaleky H.M., Zhou J.R., Thiagalingam S. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011;71:998–1008. doi: 10.1158/0008-5472.CAN-09-3269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-3269</ArticleId>
            <ArticleId IdType="pmc">PMC3075468</ArticleId>
            <ArticleId IdType="pubmed">21245094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Alexander P.B., Wang X.F. TGF-beta Family Signaling in the Control of Cell Proliferation and Survival. Cold Spring Harb. Perspect. Biol. 2017;9 doi: 10.1101/cshperspect.a022145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a022145</ArticleId>
            <ArticleId IdType="pmc">PMC5378054</ArticleId>
            <ArticleId IdType="pubmed">27920038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B., Leng C., Wu C., Zhang Z., Dou L., Luo X., Zhang B., Chen X. Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. Oncol. Rep. 2016;35:1807–1815. doi: 10.3892/or.2015.4479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2015.4479</ArticleId>
            <ArticleId IdType="pubmed">26647806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voorneveld P.W., Kodach L.L., Jacobs R.J., Liv N., Zonnevylle A.C., Hoogenboom J.P., Biemond I., Verspaget H.W., Hommes D.W., de Rooij K., et al.  Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology. 2014;147:196–208. doi: 10.1053/j.gastro.2014.03.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2014.03.052</ArticleId>
            <ArticleId IdType="pubmed">24704720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ai X., Wu Y., Zhang W., Zhang Z., Jin G., Zhao J., Yu J., Lin Y., Zhang W., Liang H., et al.  Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer. Cancer Biol. Ther. 2013;14:1059–1067. doi: 10.4161/cbt.26427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.26427</ArticleId>
            <ArticleId IdType="pmc">PMC3925661</ArticleId>
            <ArticleId IdType="pubmed">24025354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B., Halder S.K., Kashikar N.D., Cho Y.J., Datta A., Gorden D.L., Datta P.K. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 2010;138:969–980. doi: 10.1053/j.gastro.2009.11.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2009.11.004</ArticleId>
            <ArticleId IdType="pmc">PMC2831103</ArticleId>
            <ArticleId IdType="pubmed">19909744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hinshaw D.C., Shevde L.A. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019;79:4557–4566. doi: 10.1158/0008-5472.CAN-18-3962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-3962</ArticleId>
            <ArticleId IdType="pmc">PMC6744958</ArticleId>
            <ArticleId IdType="pubmed">31350295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagarsheth N., Wicha M.S., Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 2017;17:559–572. doi: 10.1038/nri.2017.49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.49</ArticleId>
            <ArticleId IdType="pmc">PMC5731833</ArticleId>
            <ArticleId IdType="pubmed">28555670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan H.X., Cao Z.B., He T.T., Huang T., Xiang C.L., Liu Y. TGFbeta1 is essential for MSCs-CAFs differentiation and promotes HCT116 cells migration and invasion via JAK/STAT3 signaling. Onco Targets Ther. 2019;12:5323–5334. doi: 10.2147/OTT.S178618.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S178618</ArticleId>
            <ArticleId IdType="pmc">PMC6615717</ArticleId>
            <ArticleId IdType="pubmed">31308702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koliaraki V., Pallangyo C.K., Greten F.R., Kollias G. Mesenchymal Cells in Colon Cancer. Gastroenterology. 2017;152:964–979. doi: 10.1053/j.gastro.2016.11.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2016.11.049</ArticleId>
            <ArticleId IdType="pubmed">28111227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamprecht S., Sigal-Batikoff I., Shany S., Abu-Freha N., Ling E., Delinasios G.J., Moyal-Atias K., Delinasios J.G., Fich A. Teaming Up for Trouble: Cancer Cells, Transforming Growth Factor-beta1 Signaling and the Epigenetic Corruption of Stromal Naive Fibroblasts. Cancers. 2018;10:61.  doi: 10.3390/cancers10030061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers10030061</ArticleId>
            <ArticleId IdType="pmc">PMC5876636</ArticleId>
            <ArticleId IdType="pubmed">29495500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z., Zhang J., Zhou J., Lu L., Wang H., Zhang G., Wan G., Cai S., Du J. Nodal Facilitates Differentiation of Fibroblasts to Cancer-Associated Fibroblasts that Support Tumor Growth in Melanoma and Colorectal Cancer. Cells. 2019;8:538.  doi: 10.3390/cells8060538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8060538</ArticleId>
            <ArticleId IdType="pmc">PMC6627322</ArticleId>
            <ArticleId IdType="pubmed">31167491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ciszewski W.M., Sobierajska K., Wawro M.E., Klopocka W., Chefczynska N., Muzyczuk A., Siekacz K., Wujkowska A., Niewiarowska J. The ILK-MMP9-MRTF axis is crucial for EndMT differentiation of endothelial cells in a tumor microenvironment. Biochim. Biophys. Acta Mol. Cell Res. 2017;1864:2283–2296. doi: 10.1016/j.bbamcr.2017.09.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2017.09.004</ArticleId>
            <ArticleId IdType="pubmed">28893556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calon A., Lonardo E., Berenguer-Llergo A., Espinet E., Hernando-Momblona X., Iglesias M., Sevillano M., Palomo-Ponce S., Tauriello D.V., Byrom D., et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 2015;47:320–329. doi: 10.1038/ng.3225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3225</ArticleId>
            <ArticleId IdType="pubmed">25706628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawinkels L.J., Paauwe M., Verspaget H.W., Wiercinska E., van der Zon J.M., van der Ploeg K., Koelink P.J., Lindeman J.H., Mesker W., ten Dijke P., et al.  Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene. 2014;33:97–107. doi: 10.1038/onc.2012.536.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.536</ArticleId>
            <ArticleId IdType="pubmed">23208491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Cespedes M.V., Sevillano M., Nadal C., Jung P., Zhang X.H., et al.  Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571–584. doi: 10.1016/j.ccr.2012.08.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2012.08.013</ArticleId>
            <ArticleId IdType="pmc">PMC3512565</ArticleId>
            <ArticleId IdType="pubmed">23153532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang Y.A., Chen Y.F., Bao Y., Mahara S., Yatim S., Oguz G., Lee P.L., Feng M., Cai Y., Tan E.Y., et al.  Hypoxic tumor microenvironment activates GLI2 via HIF-1alpha and TGF-beta2 to promote chemoresistance in colorectal cancer. Proc. Natl. Acad. Sci. USA. 2018;115:E5990–E5999. doi: 10.1073/pnas.1801348115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1801348115</ArticleId>
            <ArticleId IdType="pmc">PMC6042102</ArticleId>
            <ArticleId IdType="pubmed">29891662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tauriello D.V.F., Palomo-Ponce S., Stork D., Berenguer-Llergo A., Badia-Ramentol J., Iglesias M., Sevillano M., Ibiza S., Canellas A., Hernando-Momblona X., et al.  TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–543. doi: 10.1038/nature25492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature25492</ArticleId>
            <ArticleId IdType="pubmed">29443964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otegbeye F., Ojo E., Moreton S., Mackowski N., Lee D.A., de Lima M., Wald D.N. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS ONE. 2018;13:e0191358.  doi: 10.1371/journal.pone.0191358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0191358</ArticleId>
            <ArticleId IdType="pmc">PMC5771627</ArticleId>
            <ArticleId IdType="pubmed">29342200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dell’Aquila E., Cremolini C., Zeppola T., Lonardi S., Bergamo F., Masi G., Stellato M., Marmorino F., Schirripa M., Urbano F., et al.  Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by GONO. Ann. Oncol. 2018;29:924–930. doi: 10.1093/annonc/mdy004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdy004</ArticleId>
            <ArticleId IdType="pubmed">29324972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haram A., Boland M.R., Kelly M.E., Bolger J.C., Waldron R.M., Kerin M.J. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: A systematic review. J. Surg. Oncol. 2017;115:470–479. doi: 10.1002/jso.24523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.24523</ArticleId>
            <ArticleId IdType="pubmed">28105646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Zhao Y., Zheng F. Prognostic significance of elevated preoperative neutrophil-to-lymphocyte ratio for patients with colorectal cancer undergoing curative surgery: A meta-analysis. Medicine. 2019;98:e14126. doi: 10.1097/MD.0000000000014126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000014126</ArticleId>
            <ArticleId IdType="pmc">PMC6370071</ArticleId>
            <ArticleId IdType="pubmed">30653142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inamoto S., Kawada K., Okamura R., Hida K., Sakai Y. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: A retrospective cohort study. Int. J. Colorectal Dis. 2019;34:1303–1315. doi: 10.1007/s00384-019-03316-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00384-019-03316-z</ArticleId>
            <ArticleId IdType="pubmed">31177316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G.S., Albelda S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 2009;16:183–194. doi: 10.1016/j.ccr.2009.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.06.017</ArticleId>
            <ArticleId IdType="pmc">PMC2754404</ArticleId>
            <ArticleId IdType="pubmed">19732719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizuno R., Kawada K., Itatani Y., Ogawa R., Kiyasu Y., Sakai Y. The Role of Tumor-Associated Neutrophils in Colorectal Cancer. Int. J. Mol. Sci. 2019;20:529.  doi: 10.3390/ijms20030529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20030529</ArticleId>
            <ArticleId IdType="pmc">PMC6386937</ArticleId>
            <ArticleId IdType="pubmed">30691207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giese M.A., Hind L.E., Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133:2159–2167. doi: 10.1182/blood-2018-11-844548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-11-844548</ArticleId>
            <ArticleId IdType="pmc">PMC6524564</ArticleId>
            <ArticleId IdType="pubmed">30898857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mantovani A., Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J. Exp. Med. 2015;212:435–445. doi: 10.1084/jem.20150295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20150295</ArticleId>
            <ArticleId IdType="pmc">PMC4387285</ArticleId>
            <ArticleId IdType="pubmed">25753580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ang C.W., Nedjadi T., Sheikh A.A., Tweedle E.M., Tonack S., Honap S., Jenkins R.E., Park B.K., Schwarte-Waldhoff I., Khattak I., et al.  Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis. 2010;31:1541–1551. doi: 10.1093/carcin/bgq137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgq137</ArticleId>
            <ArticleId IdType="pubmed">20622003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gulubova M., Ananiev J., Yovchev Y., Julianov A., Karashmalakov A., Vlaykova T. The density of macrophages in colorectal cancer is inversely correlated to TGF-beta1 expression and patients’ survival. J. Mol. Histol. 2013;44:679–692. doi: 10.1007/s10735-013-9520-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10735-013-9520-9</ArticleId>
            <ArticleId IdType="pubmed">23801404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D., Qiu X., Li J., Zheng S., Li L., Zhao H. TGF-beta secreted by tumor-associated macrophages promotes proliferation and invasion of colorectal cancer via miR-34a-VEGF axis. Cell Cycle. 2018;17:2766–2778. doi: 10.1080/15384101.2018.1556064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384101.2018.1556064</ArticleId>
            <ArticleId IdType="pmc">PMC6343734</ArticleId>
            <ArticleId IdType="pubmed">30523755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai J., Xia L., Li J., Ni S., Song H., Wu X. Tumor-Associated Macrophages Derived TGF-betaInduced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells through Smad2,3-4/Snail Signaling Pathway. Cancer Res. Treat. 2019;51:252–266. doi: 10.4143/crt.2017.613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4143/crt.2017.613</ArticleId>
            <ArticleId IdType="pmc">PMC6333993</ArticleId>
            <ArticleId IdType="pubmed">29690747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling A., Lundberg I.V., Eklöf V., Wikberg M.L., Öberg Å., Edin S., Palmqvist R. The infiltration, and prognostic importance, of Th1 lymphocytes vary in molecular subgroups of colorectal cancer. J. Pathol. Clin. Res. 2015;2:21–31. doi: 10.1002/cjp2.31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cjp2.31</ArticleId>
            <ArticleId IdType="pmc">PMC4858126</ArticleId>
            <ArticleId IdType="pubmed">27499912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Havel J.J., Chowell D., Chan T.A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer. 2019;19:133–150. doi: 10.1038/s41568-019-0116-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0116-x</ArticleId>
            <ArticleId IdType="pmc">PMC6705396</ArticleId>
            <ArticleId IdType="pubmed">30755690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun X., Cui Y., Feng H., Liu H., Liu X. TGF-beta signaling controls Foxp3 methylation and T reg cell differentiation by modulating Uhrf1 activity. J. Exp. Med. 2019 doi: 10.1084/jem.20190550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20190550</ArticleId>
            <ArticleId IdType="pmc">PMC6888975</ArticleId>
            <ArticleId IdType="pubmed">31515281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shitara K., Nishikawa H. Regulatory T cells: A potential target in cancer immunotherapy. Ann. N. Y. Acad. Sci. 2018;1417:104–115. doi: 10.1111/nyas.13625.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.13625</ArticleId>
            <ArticleId IdType="pubmed">29566262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada N., Kuranaga Y., Kumazaki M., Shinohara H., Taniguchi K., Akao Y. Colorectal cancer cell-derived extracellular vesicles induce phenotypic alteration of T cells into tumor-growth supporting cells with transforming growth factor-beta1-mediated suppression. Oncotarget. 2016;7:27033–27043. doi: 10.18632/oncotarget.7041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7041</ArticleId>
            <ArticleId IdType="pmc">PMC5053630</ArticleId>
            <ArticleId IdType="pubmed">27081032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shang B., Liu Y., Jiang S.-J., Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: A systematic review and meta-analysis. Sci. Rep. 2015;5:15179. doi: 10.1038/srep15179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep15179</ArticleId>
            <ArticleId IdType="pmc">PMC4604472</ArticleId>
            <ArticleId IdType="pubmed">26462617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu G., Li Z.A., Wang S. Tumor-infiltrating FoxP3(+) Tregs predict favorable outcome in colorectal cancer patients: A meta-analysis. Oncotarget. 2017;8:75361–75371. doi: 10.18632/oncotarget.17722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.17722</ArticleId>
            <ArticleId IdType="pmc">PMC5650426</ArticleId>
            <ArticleId IdType="pubmed">29088871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cronin K.A., Lake A.J., Scott S., Sherman R.L., Noone A.-M., Howlader N., Henley S.J., Anderson R.N., Firth A.U., Ma J., et al.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018;124:2785–2800. doi: 10.1002/cncr.31551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.31551</ArticleId>
            <ArticleId IdType="pmc">PMC6033186</ArticleId>
            <ArticleId IdType="pubmed">29786848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malvezzi M., Carioli G., Bertuccio P., Boffetta P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann. Oncol. 2019;30:781–787. doi: 10.1093/annonc/mdz051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz051</ArticleId>
            <ArticleId IdType="pubmed">30887043</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
